QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against QuidelOrtho Corporation and Encourages Investors with Losses to Contact the Firm

NEW YORK , March 18, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of QuidelOrtho Corporation (NASDAQ: QDEL) resulting from allegations that QuidelOrtho may have issued materially misleading business information to the investing public. SO WHAT: If you purchased QuidelOrtho securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDEL

LOS ANGELES, CA / ACCESSWIRE / March 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against QuidelOrtho Corporation and Encourages Investors with Losses to Contact the Firm

NEW YORK , March 12, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of QuidelOrtho Corporation (NASDAQ: QDEL) resulting from allegations that QuidelOrtho may have issued materially misleading business information to the investing public. SO WHAT: If you purchased QuidelOrtho securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDEL

NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of QuidelOrtho Corporation - QDEL

QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.

QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada. The Triage PLGF test is a fluorescence immunoassay to be used with the small footprint Triage MeterPro® Instrument for the quantitative determination of placental growth factor (.

QuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in Canada

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of QuidelOrtho Corporation (NASDAQ: QDEL) resulting from allegations that QuidelOrtho may have issued materially misleading business information to the investing public. SO WHAT: If you purchased QuidelOrtho securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee.

QDEL LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation – QDEL

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced that members of its management team are scheduled to participate in the 45th Annual Raymond James Institutional Investor Conference on March 5, 2024, in Orlando, FL. Recently named Interim Chief Executive Officer, Michael Iskra, and Interim President, Rober.

QuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor Conference

NEW YORK--(BUSINESS WIRE)---- $QDEL #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of QuidelOrtho Corporation (“QuidelOrtho” or “the Company”) (NASDAQ: QDEL). Investors who purchased QuidelOrtho securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QDEL. Investigation Details: On February 13, 2024, QuidelOrtho issued a press release announcing its fourth quart.

QuidelOrtho Corporation (QDEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NASDAQ: QDEL) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your QuidelOrtho investments or would like to inquire about potentially pursuing claims to recover your loss under the federal.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of QuidelOrtho Corporation (QDEL) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NASDAQ: QDEL) investors concerning the Company's possible violations of federal securities laws. On February 21, 2024, QuidelOrtho announced that it terminated the Company's President and Chief Executive Officer. The Company further stated that the termination was an “Involuntary Termination.” If you purchased QuidelOrtho securities, ha.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of QuidelOrtho Corporation (QDEL) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NASDAQ: QDEL) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 21, 2024, QuidelOrtho announced that it terminated the Company's President and Chief Executive Officer. The Company further stated that the termination w.

The Law Offices of Frank R. Cruz Announces Investigation of QuidelOrtho Corporation (QDEL) on Behalf of Investors

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP is investigating whether QuidelOrtho Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. What if I purchased QuidelOrtho securities? If you pu.

QuidelOrtho CEO Terminated: Johnson Fistel Continues Investigation

SAN DIEGO--(BUSINESS WIRE)--The Board of Directors (the “Board”) of QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”) has made significant decisions aimed to enhance operational efficiency, drive revenue growth and deliver shareholder value. After a comprehensive evaluation, the Board has terminated Douglas Bryant, President and Chief Executive Officer of QuidelOrtho. Mr. Bryant has also resigned from the Board, both effective February 21, 2024. To ensure business continui.

QuidelOrtho Announces Changes in Executive Leadership

QuidelOrtho's fourth-quarter revenue and earnings fell year over year. The company provided disappointing full-year 2024 guidance.

Why QuidelOrtho Stock Is Crashing Today

Despite solid performances by the Labs segment and China and Other regions, QuidelOrtho (QDEL) misses earnings and revenue estimates by 41.8% and 6.9%, respectively.

QuidelOrtho (QDEL) Q4 Earnings and Sales Miss, Margins Fall

QuidelOrtho Corp.'s stock QDEL was down 33% in premarket trading on volume of 436,000 on Wednesday after the diagnostic products manufacturer missed its fourth-quarter profit and revenue estimates. The company's fourth-quarter earnings of $1.17 a share fell short of the FactSet consensus estimate of $2.04 a share.

QuidelOrtho stock drops 33% on earnings miss

The healthcare diagnostics manufacturer posted fourth-quarter results on Tuesday.

QuidelOrtho Stock Falls 40%. It's About More Than Earnings.

QuidelOrtho Corporation (QDEL) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for QuidelOrtho (QDEL) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

QuidelOrtho (QDEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

QuidelOrtho (QDEL) came out with quarterly earnings of $1.17 per share, missing the Zacks Consensus Estimate of $2.02 per share. This compares to earnings of $1.76 per share a year ago.

QuidelOrtho (QDEL) Misses Q4 Earnings and Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 31, 2023. “In our first full year operating as a combined company, we successfully laid the foundation for building a broader-based diagnostics company poised for future.

QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for QuidelOrtho (QDEL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Insights Into QuidelOrtho (QDEL) Q4: Wall Street Projections for Key Metrics

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Tuesday, February 13, 2024. Following the release of financial results, QuidelOrtho will hold a conference cal.

News for QuidelOrtho Corp Stock (QDEL)